Pan-Cancer Gene Detection

Cancer is a complex polygenic disease that is caused by the gradual accumulation of genetic mutations. When genes that regulate cell growth are mutated or damaged, the cells lose control and proliferate indefinitely, leading to the occurrence of malignant tumors. Different tumor patients may have different gene mutations that produce different responses to the same anti-tumor drug. Hence, cancer gene detection is very important and significant for cancer molecular typing, risk assessment, selection of anti-tumor medicine, and curative effect recurrence monitoring.

Equipped with powerful sequencing technologies and extensive experience in cancer gene detection and analysis, Creative Biolabs offers a wide range of high-coverage and high-resolution pan-cancer gene detection services. Our excellent bioinformatics specialists are dedicated to helping our customers to analyze cancer-specific mutations and identify drug-sensitive gene alterations that are associated with the selection of and the response to targeted therapy, immunotherapy, and chemotherapy. We also support a customized pan-cancer gene panel design and detection services based on the special requirement of your project.

  • Onco580 Gene Detection
  • The Onco580 gene panel allows for detecting 580 tumor-related genes at a time, including targeted drug related genes, chemotherapy drug related genes, tumor genetic susceptibility related genes, immune checkpoint inhibitor efficacy related genes, microsatellite instability (MSI), tumor mutation load (TMB), tumor neoantigen load (TNB), etc.

    Comparation of the detection results through Onco580 Gene Panel and WES. (Creative Biolabs Authorized) Fig. 1 Comparation of the detection results through Onco580 Gene Panel and WES.

    Features

    • Method of library: Hybrid capture
    • Number of detection genes: 580
    • Size of the panel: 1.9 Mb, covering 2.5 Mb region
    • Initial amount of DNA: 200 ng
    • Types of the detected variation: SNV, indels, CNV, and fusion
    • Sample type: tissue or blood
    • Lower limit of detection: 1% for tissue sample and 0.2% for ctDNA sample
    • Mapping ratio: ~99%
    • Coverage uniformity: ~90%
    • Sequencing platform: Illumina
  • Onco120 Gene Detection
  • The Onco120 gene panel is used to detect 120 solid tumor-related genes at a time, covering the gene information of target drugs, chemotherapeutic drug toxicity and sensitivity, immune pathways, and genes related to genetic susceptibility of tumors. Hybrid capture is used for library construction and the Illumina platform allows the detection of 120 tumor-related genes at a time with high resolution and high coverage. The detection services will accelerate your cancer research involving tumor drug development, precision medicine, and tumor early screening.

    Features

    • Method of library: Hybrid capture
    • Number of detection genes: 120
    • Size of the panel: 350 kb, covering 530 kb region
    • Initial amount of DNA: 200 ng
    • Types of the detected variation: SNV, indels, CNV, and fusion
    • Sample type: tissue or blood
    • Lower limit of detection: 1% for tissue sample and 0.2% for ctDNA sample
    • Mapping ratio: ~99%
    • Coverage uniformity: ~90%
    • Sequencing platform: Illumina, MGISEQ with custom indices
  • Onco47 Gene Detection
  • The Onco47 Gene panel is designed to detect 47 tumor-related genes, covering whole CDS regions of 3 genes and hotspots of 44 genes implicated in several cancers including non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, melanoma, and glioma.

    Features

    • Method of library: Multiplex PCR amplification
    • Number of detection genes: 47
    • Number of amplicons: 222
    • Size of the panel: 23.9 kb, covering whole CDS regions of 3 genes and hotspots of 44 genes
    • Average amplicon length: 152 bp
    • Initial amount of DNA: ≥10 ng
    • Types of the detected variation: SNV, small and medium indels
    • Sample type: Fresh tissue, blood, FFPE
    • Mapping ratio: ~98%
    • Coverage uniformity: ~98%
    • Sequencing platform: Illumina, Ion Torrent and MGISEQ with custom indices
  • Onco56 Gene Detection
  • The Onco56 Gene panel enables to detection SNVs and indels of 56 tumor-related genes, covering more than 7200 hotspots of solid tumors. The advantages of this detection are short operation time, high target rate, high mapping and specificity.

    Features

    • Method of library: Multiplex PCR amplification
    • Number of detection genes: 56
    • Number of amplicons: 251
    • Size of the panel: 24 kb
    • Initial amount of DNA: ≥10 ng
    • Types of the detected variation: SNV and indels
    • Sample type: Fresh tissue, blood, FFPE
    • Mapping ratio: ~99.8%
    • Target rate: ~99.8%
    • Coverage uniformity: ~96%
    • Sequencing platform: Illumina and MGISEQ

Creative Biolabs is dedicated to advancing and facilitating your cancer research based on an experienced expert team and state-of-the-art sequencing platforms. Our diversified gene panels allow us to help you analyze and identify multiple tumor-related gene hotspots in a highly efficient manner. If you are interested in our services, please don’t hesitate to contact us for more details. We look forward to discussing your inquiry and finding the best solution for your needs.

Resources

Infographics

Podcast

Note: Our sequencing services are for Research Use Only. Not For Clinical Diagnosis.
Related Services:
  1. Cancer-Specific Gene Detection
Online Inquiry
ISO 9001 Certified - Creative Biolabs Quality Management System.
logo
Inquiry Basket